Contact UsHome

Presentations & Events

Presentations

Date	Documents
Sep 05, 2018	Add Files Aeglea BioTherapeutics Corporate Presentation 2 MB

Upcoming Events

Date	Title
Summary Toggle Oct 16-20, 2018	American Society of Human Genetics (ASHG) Annual Meeting Title #1: Improvements in Arginase 1 Deficiency-related disease manifestations following plasma arginine reduction with pegzilarginase: early Phase 2 results Title #2: Improved survival and amelioration of disease-related liver pathology in a mouse model of homocystinuria with a novel homocysteine degrading enzyme Title #3: Clinical features of Arginase 1 Deficiency: Review of Literature Case Series
Summary Toggle Oct 17, 2018 8:30 AM EDT	Aeglea BioTherapeutics Clinical Data Update Click here for webcast Supporting Materials Aeglea BioTherapeutics to Present New Interim Phase 1/2 Clinical Trial Data in Arginase 1 Deficiency at 2018 ASHG Annual Meeting
Summary Toggle Oct 21, 2018 1:35 PM CDT	European Society for Medical Oncology (ESMO) 2018 Congress Title: Initial cohort expansion results of sustained arginine depletion with pegzilarginase in melanoma patients in a Phase 1 advanced solid tumor trial
Summary Toggle Oct 26, 2018 5:54 PM PDT	American Society of Nephrology (ASN)

Past Events

Date	Title
Summary Toggle Apr 18, 2016	American Association for Cancer Research (AACR) Annual Meeting – AEB1102 Supporting Materials American Association for Cancer Research (AACR) Annual Meeting – AEB1102 1.5 MB Aeglea BioTherapeutics to Present New Data at American Association for Cancer Research (AACR) Annual Meeting
Summary Toggle Apr 19, 2016	American Association for Cancer Research (AACR) Annual Meeting – AEB3103 Supporting Materials American Association for Cancer Research (AACR) Annual Meeting – AEB3103 575.2 KB Aeglea BioTherapeutics to Present New Data at American Association for Cancer Research (AACR) Annual Meeting
Summary Toggle Nov 11, 2016	Society for Immunotherapy of Cancer (SITC) 2016 Annual Meeting – AEB1102 Supporting Materials Society for Immunotherapy of Cancer (SITC) 2016 Annual Meeting – AEB1102 1.6 MB Aeglea BioTherapeutics to Present a Poster at the Society for Immunotherapy of Cancer 2016 Annual Meeting Suggesting Potential for AEB1102 Combination Therapy with Immuno-Oncology Checkpoint Inhibitors
Summary Toggle Dec 03, 2016	Aeglea BioTherapeutics, Inc. at 58th Annual American Society of Hematology (ASH) Meeting Supporting Materials ASH Poster 1.3 MB
Summary Toggle Mar 06, 2017	Aeglea BioTherapeutics, Inc. at Keystone Symposia Conference on Tumor Metabolism - AEB1102 Supporting Materials Aeglea BioTherapeutics, Inc. at Keystone Symposia Conference on Tumor Metabolism - AEB1102 3.3 MB Aeglea BioTherapeutics to Present Preclinical Data for AEB1102 at Keystone Symposia Conference on Tumor Metabolism
Summary Toggle Mar 23, 2017	Aeglea BioTherapeutics to Present Topline Data from Phase 1 Trial of AEB1102 for Treatment of Arginase I Deficiency at 2017 ACMG Annual Clinical Genetics Meeting Supporting Materials Aeglea BioTherapeutics, Inc. at ACMG Annual Clinical Genetics Meeting – Topline Data from Phase 1 Trial of AEB1102 for Treatment of Arginase I Deficiency 1.9 MB
Summary Toggle Mar 24, 2017	Aeglea BioTherapeutics at American College of Medical Genetics and Genomics Annual Clinical Genetics Meeting. Supporting Materials Newborn Screening for Arginase Deficiency in the U.S. 2.4 MB
Summary Toggle Apr 04, 2017	Aeglea BioTherapeutics to Present Preclinical Data for AEB1102 at 2017 AACR Annual Meeting Supporting Materials Aeglea BioTherapeutics to Present Preclinical Data for AEB1102 at 2017 AACR Annual Meeting 11.4 MB Aeglea BioTherapeutics to Present Preclinical Data for AEB1102 at 2017 AACR Annual Meeting
Summary Toggle Nov 10, 2017	Aeglea BioTherapeutics to Present Preclinical Data at 2017 Society for Immunotherapy of Cancer (SITC) Annual Meeting Supporting Materials Aeglea BioTherapeutics to Present Preclinical Data at 2017 Society for Immunotherapy of Cancer (SITC) Annual Meeting 1.7 MB
Summary Toggle Jan 22, 2018	Aeglea BioTherapeutics to Present Preclinical Data at 2018 Keystone Symposia Tumor Metabolism Conference Supporting Materials Aeglea BioTherapeutics to Present Preclinical Data at 2018 Keystone Symposia Tumor Metabolism Conference 2.6 MB Aeglea BioTherapeutics to Present Preclinical Data at 2018 Keystone Symposia Tumor Metabolism Conference
Summary Toggle Mar 12, 2018	Aeglea BioTherapeutics to Present Adult Repeat Dose Data at 2018 Annual Meeting of The Society for Inherited Metabolic Disorders Supporting Materials Aeglea BioTherapeutics to Present Adult Repeat Dose Data at 2018 Annual Meeting of The Society for Inherited Metabolic Disorders 1.3 MB Aeglea BioTherapeutics to Present Adult Repeat Dose Data at 2018 Annual Meeting of The Society for Inherited Metabolic Disorders
Summary Toggle Apr 12, 2018	Aeglea BioTherapeutics Clinical Data Update Supporting Materials Weekly Pegzilarginase Produced Marked and Sustained Reductions in Guanidino Compounds in Adults with Arginase 1 Deficiency: Early Phase 1/2 Results 1.5 MB Aeglea BioTherapeutics Presents New Phase 1/2 Trial Data Demonstrating Clinically Relevant Treatment Effects in Arginase 1 Deficiency Patients at the 2018 ACMG Annual Clinical Genetics Meeting
Summary Toggle Apr 15, 2018	American Association for Cancer Research (AACR) Annual Meeting Supporting Materials Phase 1 Dose Escalation Trial of Pegzilarginase in Patients with Advanced Solid Tumors 1.5 MB Depletion of Blood Arginine with Pegzilarginase in Combination with anti-PD-L1 Increases Tumor Infiltration by Immune Cells and Enhances anti-Tumor Activity 553.4 KB
Summary Toggle Jun 04, 2018	Aeglea BioTherapeutics to Present at 2018 ASCO Annual Meeting Supporting Materials Phase 1 trial of Pegzilarginase in patients with relapsed/refractory (R/R) AML or MDS refractory to hypomethylating agents (HMAs) 1.8 MB
Summary Toggle Sep 04-07, 2018	Annual Symposium of the Society for the Study of Inborn Errors of Metabolism (SSIEM) Title: Improvements in Arginase 1 Deficiency-related disease manifestations following plasma arginine reduction with pegzilarginase Supporting Materials Improvements in Arginase 1 Deficiency-Related Disease Manifestations Following Plasma Arginine Reduction With Pegzilarginase 6.2 MB
Summary Toggle Sep 04, 2018	Aeglea BioTherapeutics Clinical Data Update Click here for webcast Supporting Materials Aeglea BioTherapeutics to Present New Interim Phase 1/2 Clinical Trial Data in Arginase 1 Deficiency at 2018 SSIEM Annual Symposium